These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32734632)

  • 1. Usefulness of neuron-specific enolase as a serum marker of metastatic melanoma.
    Sato S; Kato J; Sawada M; Horimoto K; Okura M; Hida T; Uhara H
    J Dermatol; 2020 Oct; 47(10):1141-1148. PubMed ID: 32734632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course.
    Zeltzer PM; Marangos PJ; Evans AE; Schneider SL
    Cancer; 1986 Mar; 57(6):1230-4. PubMed ID: 3002599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuron specific enolase (NSE) in serum of patients with malignant melanoma.
    Wibe E; Paus E; Aamdal S
    Cancer Lett; 1990 Jun; 52(1):29-31. PubMed ID: 2354416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects.
    Isgrò MA; Bottoni P; Scatena R
    Adv Exp Med Biol; 2015; 867():125-43. PubMed ID: 26530364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma.
    Wibe E; Hannisdal E; Paus E; Aamdal S
    Eur J Cancer; 1992; 28A(10):1692-5. PubMed ID: 1389487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker.
    Fischer GM; Carapeto FCL; Joon AY; Haydu LE; Chen H; Wang F; Van Arnam JS; McQuade JL; Wani K; Kirkwood JM; Thompson JF; Tetzlaff MT; Lazar AJ; Tawbi HA; Gershenwald JE; Scolyer RA; Long GV; Davies MA
    Cancer Med; 2020 Nov; 9(22):8650-8661. PubMed ID: 33016647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-100 and NSE as serum markers in melanoma.
    Tofani A; Cioffi RP; Sciuto R; Rea S; Festa A; Di Filippo F; Cavaliere R; Maini CL
    Acta Oncol; 1997; 36(7):761-4. PubMed ID: 9490097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuron-specific enolase (NSE)--a suitable tumor marker in malignant melanoma?].
    Hornef S; Lux J; Rassner G
    Hautarzt; 1992 Feb; 43(2):77-80. PubMed ID: 1347764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuron-specific enolase as a tumor marker in metastatic melanoma.
    Buzaid AC; Sandler AB; Hayden CL; Scinto J; Poo WJ; Clark MB; Hotchkiss S
    Am J Clin Oncol; 1994 Oct; 17(5):430-1. PubMed ID: 8092117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of serum S100 in metastatic malignant melanoma.
    Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
    Eur J Cancer; 1995 Oct; 31A(11):1898-902. PubMed ID: 8541129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Neuron-Specific Enolase Is Related to Cerebellar Connectivity: A Resting-State Functional Magnetic Resonance Imaging Pilot Study.
    Schroeter ML; Mueller K; Arelin K; Sacher J; Holiga Š; Kratzsch J; Luck T; Riedel-Heller S; Villringer A
    J Neurotrauma; 2015 Sep; 32(17):1380-4. PubMed ID: 24844267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuron-specific enolase--a serum tumour marker in seminoma?
    Fosså SD; Klepp O; Paus E
    Br J Cancer; 1992 Feb; 65(2):297-9. PubMed ID: 1739633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer.
    van Zandwijk N; Jassem E; Bonfrer JM; Mooi WJ; van Tinteren H
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):37-43. PubMed ID: 1329221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer.
    Jørgensen LG; Hansen HH; Cooper EH
    Eur J Cancer Clin Oncol; 1989 Jan; 25(1):123-8. PubMed ID: 2537729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.
    Kiniwa Y; Nakamura K; Mikoshiba A; Ashida A; Akiyama Y; Morimoto A; Okuyama R
    BMC Cancer; 2021 Mar; 21(1):287. PubMed ID: 33731038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum neuron specific enolase: can it be a tumour marker for renal cell carcinoma?
    Yaman O; Baltaci S; Arikan N; Ozdiler E; Göğüş O; Müftüoğlu YZ
    Int Urol Nephrol; 1996; 28(2):207-10. PubMed ID: 8836790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of serum S100 in metastatic malignant melanoma.
    Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
    Eur J Cancer; 1995 Jun; 31A(6):924-8. PubMed ID: 7646923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy.
    Liu X; Zhang W; Yin W; Xiao Y; Zhou C; Hu Y; Geng S
    Medicine (Baltimore); 2017 Nov; 96(46):e8258. PubMed ID: 29145241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age dependence and prognostic impact of neuron specific enolase (NSE) in children with neuroblastoma.
    Berthold F; Engelhardt-Fahrner U; Schneider A; Schumacher R; Zieschang J
    In Vivo; 1991; 5(3):245-7. PubMed ID: 1893081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neuron-specific enolase and beta 2-microglobulin in the serum of patients with melanoma].
    Uerlich M; Biltz H; Kreysel HW
    Immun Infekt; 1988 Apr; 16(2):65-7. PubMed ID: 3292403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.